https://newsroom.astellas.com/ https://newsroom.astellas.com/2025-10-01-VYLOY-R-zolbetuximab-in-Combination-with-Chemotherapy-for-Advanced-Gastric-or-Gastroesophageal-Junction-Cancer-is-now-funded-in-both-Ontario-and-Quebec MARKHAM, ON, Oct. 1, 2025 /CNW/ - Astellas Pharma Canada Inc. is proud to announce that VYLOY® (zolbetuximab) is now funded by the Ontario Drug Benefit Program under the New Drug Funding Program... Wed, 01 Oct 2025 12:43:00 -0400 https://newsroom.astellas.com/2025-10-01-VYLOY-R-zolbetuximab-in-Combination-with-Chemotherapy-for-Advanced-Gastric-or-Gastroesophageal-Junction-Cancer-is-now-funded-in-both-Ontario-and-Quebec https://newsroom.astellas.com/2025-07-02-XTANDI-R-enzalutamide-now-funded-in-Ontario-for-all-approved-prostate-cancer-indications XTANDI is the first and only androgen receptor pathway inhibitor (ARPI) indicated and reimbursed in Ontario for use in patients with nmCSPC with biochemical recurrence at high risk for metastasis... Wed, 02 Jul 2025 09:19:00 -0400 https://newsroom.astellas.com/2025-07-02-XTANDI-R-enzalutamide-now-funded-in-Ontario-for-all-approved-prostate-cancer-indications https://newsroom.astellas.com/2025-03-18-VEOZAH-R-fezolinetant-film-coated-tablets-Now-Available-in-Canada,-First-and-Only-Non-hormonal-NK3-Antagonist-Indicated-for-Vasomotor-Symptoms-VMS-Associated-with-Menopause VEOZAH® (fezolinetant film-coated tablets) Now Available in Canada, First and Only Non-hormonal NK3 Antagonist Indicated for Vasomotor Symptoms (VMS) Associated with Menopause New treatment... Tue, 18 Mar 2025 10:53:00 -0400 https://newsroom.astellas.com/2025-03-18-VEOZAH-R-fezolinetant-film-coated-tablets-Now-Available-in-Canada,-First-and-Only-Non-hormonal-NK3-Antagonist-Indicated-for-Vasomotor-Symptoms-VMS-Associated-with-Menopause https://newsroom.astellas.com/2025-03-03-New-research-spotlights-global-and-Canadian-perceptions-of-menopause-and-the-impact-of-enduring-stigma-on-womens-mental-health,-healthcare-and-careers MARKHAM, ON, March 3, 2025 /CNW/ - Astellas Pharma Canada Inc. is pleased to share new findings from the Menopause Experience & Attitudes Study (MEAS), an international study examining societal... Mon, 03 Mar 2025 19:55:00 -0500 https://newsroom.astellas.com/2025-03-03-New-research-spotlights-global-and-Canadian-perceptions-of-menopause-and-the-impact-of-enduring-stigma-on-womens-mental-health,-healthcare-and-careers https://newsroom.astellas.com/2025-01-09-Astellas-Receives-Health-Canada-Approval-for-VYLOY-R-zolbetuximab-in-Combination-with-Chemotherapy-for-Advanced-Gastric-and-Gastroesophageal-Junction-Cancer Astellas Receives Health Canada Approval for VYLOY® (zolbetuximab) in Combination with Chemotherapy for Advanced Gastric and Gastroesophageal Junction Cancer VYLOY is the first and only therapy... Thu, 09 Jan 2025 10:59:00 -0500 https://newsroom.astellas.com/2025-01-09-Astellas-Receives-Health-Canada-Approval-for-VYLOY-R-zolbetuximab-in-Combination-with-Chemotherapy-for-Advanced-Gastric-and-Gastroesophageal-Junction-Cancer